Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer

Fierce Pharma October 12, 2023
Angus Liu

Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence.

The FDA has approved Pfizer’s Braftovi and Mektovi for treating metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, the agency said Wednesday.

Pfizer reached this treatment setting late, though. The new approval comes more than six years after Novartis won the FDA’s go-ahead for its own BRAF-MEK combo, Tafinlar and Mekinist, in the same BRAF-mutant NSCLC setting.

In fact, the Novartis cocktail last year snagged a tumor-agnostic label to treat any advanced solid tumors with the BRAF V600E mutation following prior therapy or in patients who have no alternative treatment options.

BRAF...

Today's Sponsors

Today's Sponsor